# EDGAR Filing Document

**Accession Number:** 0002058263
**File Stem:** 0001049169-26-000693
**Filing Date:** 2026-2
**Character Count:** 36106
**Document Hash:** 266f01c431b9131ac06446cc64391673
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001049169-26-000693.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0001049169-26-000693

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251231

**FILED AS OF DATE**: 20260227

**DATE AS OF CHANGE**: 20260227

**PERIOD START**: 20260331

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Carlyle AlpInvest Private Markets Secondaries Fund
- **CENTRAL INDEX KEY:** 0002058263

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** NY

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-24059
- **FILM NUMBER:** 26702033

**BUSINESS ADDRESS:**
- **STREET 1:** C/O ALPINVEST US HOLDINGS, LLC
- **STREET 2:** ONE VANDERBILT AVENUE, SUITE 3400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 646-735-4293

**MAIL ADDRESS:**
- **STREET 1:** C/O ALPINVEST US HOLDINGS, LLC
- **STREET 2:** ONE VANDERBILT AVENUE, SUITE 3400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

## Nport-Ex

**CARLYLE ALPINVEST PRIVATE MARKETS SECONDARIES FUND**

**CONSOLIDATED SCHEDULE OF INVESTMENTS (Unaudited)**

**As of December 31, 2025**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Private Equity Investments (57.1%)** | **Footnotes** | **Acquisition Date** | **Cost Value** | **Fair Value** <sup>(2)</sup> |
| **Secondary Investments (57.1%)** | (5)(6)(7) |  |  |  |
| &nbsp;&nbsp;**Europe (24.1%)** |  |  |  |  |
| Alto Capital V | (3) | 12/31/2025 | $1719904 | $2375006 |
| Apheon AlliA | (4) | 12/31/2025 | 37 |  |
| Apheon MidCap Buyout IV, SCSp | (3) | 12/31/2025 | 11605919 | 18918979 |
| Apheon MidCap Buyout VI SCSp | (4) | 12/31/2025 | 37 |  |
| Apheon Opseo Long Term Value Fund SCSp | (3) | 12/31/2025 | 7316733 | 11866685 |
| Apheon Svt Long Term Value Fund SCSp | (3) | 12/31/2025 | 5904806 | 9238958 |
| Backed 1, L.P. | (4) | 12/31/2025 | 1846794 | 4242919 |
| Backed 2, L.P. | (4) | 12/31/2025 | 1099797 | 2013595 |
| Bregal Unternehmerkapital IV-B SCSp | (4) | 12/31/2025 | 1272869 | 1375392 |
| E.C.B. (Bastille) SCA | (3) | 12/31/2025 | 1290649 | 1173361 |
| ECI 12 Special Purpose, L.P. | (3) | 9/30/2025 | 14559031 | 15422302 |
| Elysium Acquisition, L.P. | (3) | 9/30/2025 | 9217004 | 9906951 |
| Epiris Fund III (B), L.P. | (4) | 12/31/2025 | 2255142 | 3796391 |
| Hg Saturn 4 B, L.P. | (3) | 12/31/2025 | 19275 | 15523 |
| KKR Azur Co-lnvest, L.P. | (3) | 12/31/2025 | 4959389 | 4934429 |
| KKR Rainbow Co-lnvest (Asset), L.P. | (3) | 12/31/2025 | 3564690 | 5887671 |
| KKR Sigma Co-lnvest II, L.P. | (3) | 12/31/2025 | 8178265 | 13070560 |
| Portage Capital Solutions Intenational Fund I, L.P. | (4) | 12/31/2025 | 1458040 | 1985543 |
| PrimeStone Capital Fund ICAV | (3) | 12/31/2025 | 407305 | 688427 |
| Providence Strategic Growth Europe, L.P. | (4) | 9/30/2025 | 1993492 | 2095628 |
| PSG Europe II, L.P. | (4) | 9/30/2025 | 1140695 | 1164502 |
| Sagard 3 FPCI | (3) | 12/31/2025 | 7269652 | 6485669 |
| Sagard 4A FPCI and Sagard 4B FIPS (A Shares) | (4) | 12/31/2025 | 16305429 | 11427746 |
| Sagard II-A FPCI and Sagard II-B FPCI | (3) | 12/31/2025 | 293426 | 309358 |
| Sagard NewGen FPCI | (3) | 12/31/2025 | 2983261 | 2527955 |
| Sagard NewGen Pharma FPCI | (3) | 12/31/2025 | 1056263 | 747289 |
| Sagard Testing FPCI | (4) | 12/31/2025 | 6020314 | 4497517 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total Europe** |  |  | $113738218 | $136168356 |
| &nbsp;&nbsp;**North America (33.0%)** |  |  |  |  |
| Audax Private Equity Beacon CF | (3) | 9/30/2025 | 17905961 | 21305683 |
| Bain Capital Beacon Holdings, L.P. | (3) | 9/30/2025 | 33204292 | 29427068 |
| C2 Capital Global Export-To-China Fund, L.P. | (4) | 12/31/2025 | 5222404 | 10456641 |
| CF24XB SCSp | (3) | 9/30/2025 | 11796244 | 12263709 |
| Churchill Secondary Partners II, L.P. | (3) | 11/3/2025 | 6804343 | 6463579 |
| GA Continuity Fund II, L.P. | (3) | 9/30/2025 | 6006717 | 6240384 |
| Hidden Harbor Capital Partners Continuation Fund, L.P. | (3) | 9/30/2025 | 15162905 | 14002899 |

---

------

**CARLYLE ALPINVEST PRIVATE MARKETS SECONDARIES FUND**

**CONSOLIDATED SCHEDULE OF INVESTMENTS (Unaudited) (continued)**

**As of December 31, 2025**

---

| | | | | |
|:---|:---|:---|:---|:---|
| LEP Red Rock Fund, L.P. | (3) | 10/8/2025 | 10337062 | 11990992 |
| Madison Dearborn Capital Partners IX | (3) | 10/8/2025 | 147118 | 131148 |
| Madison Dearborn Capital Partners VIII | (3) | 9/30/2025 | 1647586 | 1757140 |
| One Equity Partners IX-B SCSp | (4) | 12/31/2025 | 2664470 | 2859694 |
| Peak Rock Capital Fund IV-C NUS | (4) | 12/31/2025 | 304141 | 304050 |
| Providence Strategic Growth II, L.P. | (4) | 9/30/2025 | 869869 | 894961 |
| Providence Strategic Growth III, L.P. | (4) | 9/30/2025 | 1831336 | 1840293 |
| Providence Strategic Growth IV, L.P. | (4) | 9/30/2025 | 2730314 | 2790298 |
| Providence Strategic Growth, L.P. | (4) | 9/30/2025 | 182852 | 180803 |
| PSG Fidelity Co-Invest, L.P. | (4) | 9/30/2025 | 1105243 | 1139449 |
| PSG LM Sequel, L.P. | (4) | 10/3/2025 | 190982 | 190982 |
| PSG LM Sequel, L.P. | (4) | 10/3/2025 | 101078 | 101078 |
| PSG V, L.P. | (4) | 9/30/2025 | 2726949 | 2778561 |
| PSG VI, L.P. | (4) | 9/30/2025 | 301470 | 275463 |
| Stone Point CV, L.P. | (3) | 10/13/2025 | 24182881 | 24182181 |
| The Resolute III Continuation Fund, L.P. | (3) | 9/30/2025 | 37184069 | 34426256 |
| Warburg Pincus Capital Solutions Founders Fund, L.P. | (4) | 12/31/2025 | 377486 | 952744 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total North America** |  |  | $182987772 | $186956056 |
| **Total Secondary Investments** |  |  | $296725990 | $323124412 |
| **Total Private Equity Investments** |  |  | $296725990 | $323124412 |
| **Cash Equivalents (52.4%)** |  |  |  |  |
| &nbsp;&nbsp;**North America (52.4%)** |  |  |  |  |
| UMB Money Market II Special (3.4%) | (3)(4)(5) |  | $297046414 | $297046414 |
| **Total Cash Equivalents** |  |  | $297046414 | $297046414 |
| **Total Investments and Cash Equivalents (109.5%)** |  |  | $593772404 | $620170826 |
| **Total Other Assets and Liabilities, Net (-9.5%)** |  |  |  | $(53818660) |
| **Total Net Assets (100.0%)** |  |  |  | $**566352166** |

---

(1) The Fair Value is estimated by management using significant unobservable inputs and as such may not necessarily reflect the current or expected future performance of such Primary Investment or Secondary Investment or the Fair Value of the Fund's interest in such Primary Investment or Secondary Investment. Furthermore, the Fair Value has not been calculated, reviewed, verified or in any way approved by such Primary Investment or Secondary Investment or its general partner, manager or sponsor (including any of its affiliates). Please see Notes to Consolidated Schedule of Investments for further details regarding the valuation policy of the Fund.

(2) Secondary Investments are portfolios of assets acquired on the secondary market.

(3) Investments held in AlpInvest Seed Fund II, L.P.

(4) Investments held in AlpInvest CAPS Blocker, LLC

(5) Investment does not issue shares.

(6) Non-income producing security.

(7) Private Equity Investments are generally issued in private placement transactions and as such are generally restricted as to resale. Each investment may have been purchased on various dates and for different amounts. The date of the first purchase is reflected under Acquisition Date as shown in the Consolidated Schedule of Investments. Total fair value of restricted investments as of December 31, 2025, was $323,124,412, or 57.1%, of net assets.

*See accompanying Notes to Consolidated Schedule of Investments.*

------

**CARLYLE ALPINVEST PRIVATE MARKETS SECONDARIES FUND**

**NOTES TO CONSOLIDATED SCHEDULE OF INVESTMENTS (Unaudited)**

**As of December 31, 2025**

**1. ORGANIZATION**

Carlyle AlpInvest Private Markets Secondaries Fund (the "Fund") was organized as a Delaware statutory trust on January 30, 2025. The Fund is registered under the Investment Company Act of 1940, as amended (the "1940 Act"), as a non-diversified, closed-end management investment company. The Fund commenced operations on November 3, 2025.

The Fund's Board of Trustees (the "Board") provides broad oversight over the Fund's investment program and its management and operations. AlpInvest Private Equity Investment Management, LLC serves as the Fund's investment adviser ("AlpInvest"). AlpInvest oversees the management of the Fund's day-to-day activities including structuring, governance, distribution, reporting and oversight. AlpInvest entered into a sub-advisory agreement with Carlyle Global Credit Investment Management L.L.C., who serves as the Fund's sub-adviser ("Sub-Adviser" and together with AlpInvest, the "Advisers") and actively manages the portion of the Fund's assets allocated to liquid fixed-income investments. Each Adviser is registered as an investment adviser with the Securities and Exchange Commission (the "SEC") under the Investment Advisers Act of 1940, as amended. Each Adviser is also an indirect, wholly-owned subsidiary of The Carlyle Group Inc.

The Fund's investment objective is to seek long-term capital appreciation. The Fund opportunistically allocates its assets across a global portfolio of private markets investments ("Private Markets Investments"). Under normal circumstances, the Fund intends to invest at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in Secondary Investments. For purposes of this policy, "Secondary Investments" include, without limitation:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• acquisitions of privately owned portfolios, consisting primarily of single- or multiple-limited partner commitments in unaffiliated private funds ("Underlying Funds") acquired from existing investors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• investments involving partnering with a general partner of an Underlying Fund across a range of transaction settings and structures, with the objective of gaining exposure to one or more existing investments, often structured as continuation funds, spin-outs, fund recapitalizations, stapled secondaries, and direct asset purchases; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• primary investments in existing Underlying Funds that have committed and reserved at least 50% of their assets to portfolio investments at the time of the Fund's commitment ("Substantially Invested Underlying Funds"). In addition, the Fund may invest up to 10% of its assets in Underlying Funds during their original issue not in connection with any Secondary Investment ("Primary Investments").

As part of its principal investment strategies, the Fund invests in underlying funds and portfolio companies organized both within and outside of the United States. The Fund may invest in fixed income investments in order to manage its cash and liquidity needs while earning an incremental return.

**2. SIGNIFICANT ACCOUNTING POLICIES**

*Basis of Presentation* – The Consolidated Schedule of Investments has been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"). The Fund is considered an investment company and therefore applies the guidance of Financial Accounting Standards Board Accounting Standards Codification ("ASC") Topic 946, Financial Services - Investment Companies. The preparation of the Consolidated Schedule of Investments requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Consolidated Schedule of Investments and the reported amounts of income and expenses for the period. Actual results could differ from those estimates. The consolidated Schedule of Investments include the accounts of the Fund and its wholly owned subsidiaries ("Subsidiaries"). The following is a summary of significant accounting policies used in preparing the Consolidated Schedule of Investments.

*Consolidation of a Subsidiary* – The Fund may make investments through its Subsidiaries. Such Subsidiaries will not be registered under the 1940 Act. The Board has oversight responsibility for the investment activities of the Fund, including its investment in any Subsidiary. To the extent applicable to the investment activities of a Subsidiary, the Subsidiary will follow the same compliance policies and procedures as the Fund. The Fund would "look through" any such Subsidiary to determine compliance with its investment policies. The Consolidated Schedule of Investments of the

------

**CARLYLE ALPINVEST PRIVATE MARKETS SECONDARIES FUND**

**NOTES TO CONSOLIDATED SCHEDULE OF INVESTMENTS (Unaudited) (continued)**

Fund includes AlpInvest Seed Fund II, L.P. and AlpInvest CAPS Blocker LLC, both wholly-owned subsidiaries of the Fund.

*Valuation* – Portfolio securities are valued at market value determined on the basis of market quotations or, if market quotations are not readily available or are unreliable, at fair value as determined in accordance with the policies and procedures approved by and under the oversight of the Board. Pursuant to these policies and procedures, AlpInvest, as the Fund's investment adviser, serves as the Fund's valuation designee pursuant to Rule 2a-5 of the 1940 Act. In this capacity, the Adviser is responsible, among other things, for making all fair value determinations relating to all of the Fund's investments, subject to the Board's oversight.

The Fund values its Private Markets Investments at fair value consistent with the principles of ASC Topic 820, Fair Value Measurements ("ASC 820"). For liquid investments that are publicly traded or for which market quotations are available, valuations are generally based on the closing sales prices as of the valuation date. See Note 3, "Fair Value Measurements".

**3. FAIR VALUE MEASUREMENTS**

The Fund follows the provisions of ASC 820-10, *Fair Value Measurements and Disclosures*, which among other matters, requires enhanced disclosures about investments that are measured and reported at fair value. ASC 820-10 defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP and expands disclosure of fair value measurements. ASC 820-10 determines fair value to be the price that would be received for an investment in a current sale, which assumes an orderly transaction between market participants on the measurement date. ASC 820-10 requires the Fund to assume that the portfolio investment is sold in its principal market to market participants or, in the absence of a principal market, the most advantageous market, which may be a hypothetical market. Market participants are defined as buyers and sellers in the principal or most advantageous market that are independent, knowledgeable, and willing and able to transact. In accordance with ASC 820-10, the Fund has considered its principal market as the market in which the Fund exits its portfolio investments with the greatest volume and level of activity. ASC 820-10 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. In accordance with ASC 820-10, these inputs are summarized in the three broad levels listed below:

The three-tier hierarchy of inputs is summarized below:

Level 1 — Inputs that reflect unadjusted quoted prices in active markets for identical financial instruments that the reporting entity has the ability to access at the measurement date.

Level 2 — Inputs other than quoted prices included within Level 1 that are observable for the financial instrument, either directly or indirectly. Level 2 inputs also include quoted prices for similar assets and liabilities in active markets, and quoted prices for identical or similar assets and liabilities in markets that are not active.

Level 3 — Significant unobservable inputs for the financial instrument (including management's own assumptions in determining the fair value of investments).

*Underlying Funds* – Investments in Underlying Funds are recorded at fair value, using the Underlying Funds' net asset value as a "practical expedient," in accordance with ASC 820-10.

Investments in Underlying Funds generally are restricted securities that are subject to substantial holding periods and are not traded in public markets. Accordingly, the Fund may not be able to resell some of its investments for extended periods, which may be several years. The types of Underlying Funds that the Fund may make investments in include Primary and Secondary Investments. Primary Investments are investments in newly established private equity funds. Secondary Investments are investments in existing private equity funds that are acquired in privately negotiated transactions.

The fair value relating to certain underlying investments of these Underlying Funds, for which there is no public market, has been estimated by the respective Underlying Funds' management and is based upon available information in the absence of readily ascertainable fair values and does not necessarily represent amounts that might ultimately be

------

**CARLYLE ALPINVEST PRIVATE MARKETS SECONDARIES FUND**

**NOTES TO CONSOLIDATED SCHEDULE OF INVESTMENTS (Unaudited) (continued)**

realized. Due to the inherent uncertainty of valuation, those estimated fair values may differ significantly from the values that would have been used had a public market for the investments existed. These differences could be material.

AlpInvest will adjust the fair value provided by the Underlying Fund's management for subsequent cash flows received from or distributed to the Underlying Funds and for any changes in the market prices of public securities held by the Underlying Funds and may also apply a market adjustment to reflect the estimated change in the fair value of the Underlying Funds non-public investments from the date of the most recent net asset value provided by the Underlying Fund's management.

The following table is a summary of information about the levels within the fair valuation hierarchy at which the Fund's investments are measured as of December 31, 2025:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Investments** | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Cash Equivalents | $297046414 | $— | $— | $297046414 |
| Total | $297046414 | $— | $— | $297046414 |

---

The Fund held Secondary Investments with a fair value of $323,124,412, which are excluded from the fair value hierarchy as of December 31, 2025, in accordance with Subtopic 820-10 as investments in Underlying Funds valued at net asset value, as a "practical expedient" are not required to be included in the fair value hierarchy.

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Carlyle AlpInvest Private Markets Secondaries Fund

- **b. Investment Company Act file number:** 811-24059

- **c. CIK number of Registrant:** 0002058263

- **d. LEI of Registrant:** 391200LRBA10W6EECT04

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** ONE VANDERBILT AVENUE SUITE 3400

  - **City:** NEW YORK

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10017

  - **Telephone number:** 6467354293

**Item A.2. Information about the Series.**

- **a. Name of Series:** Carlyle AlpInvest Private Markets Secondaries Fund

- **c. LEI of Series:** 391200LRBA10W6EECT04

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2026-03-31

- **b. Date as of which information is reported:** 2025-12-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $622193197.62

**Total Liabilities:** $55841031.43

**Net Assets:** $566352166.19

**Delayed Delivery Securities:** $157669928.66

**Cash Not Reported:** $6447229.38

**Monthly Return Information**

| Class        | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID N/A |  |  | 4.64%                |
| Class ID N/A |  |  | 4.64%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $0.00                    | $0.00                                      |
| Month 2  | $-312.96                 | $-2963406.81                               |
| Month 3  | $15386.71                | $29356155.32                               |

### Schedule of Portfolio Investments

| Name   | Title                                                 | Identifiers                  | Payoff Profile   | Asset Category   | Issuer Category   | Country   | Balance   | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   | Fair Value Level   | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| N/A    | Apheon Svt Long Term Value Fund SCSp                  | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | BE        |  | OU      | $9238957.92   | 1.63%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Audax Private Equity Beacon CF                        | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $21305682.58  | 3.76%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Sagard 3 FPCI                                         | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | FR        |  | OU      | $6485668.80   | 1.15%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Apheon Opseo Long Term Value Fund SCSp                | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | BE        |  | OU      | $11866684.58  | 2.10%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Churchill Secondary Partners II,L.P.                  | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $6463578.65   | 1.14%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Madison Dearborn Capital Partners VIII                | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $1757140.08   | 0.31%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | MONEY MARKET II                                       | CUSIP: SF8888628<br>LEI: N/A | Long             | STIV             | RF                | US        | 290599185 | NS      | $290599184.68 | 51.31%            |  |  |  | No            | 1                  | On Loan: No      |
| N/A    | Backed 1 LP                                           | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | JE        |  | OU      | $4242918.88   | 0.75%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Apheon MidCap Buyout VI, SCSp                         | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | BE        |  | OU      | $0.00         | 0.00%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Providence Strategic Growth Europe L.P.               | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | KY        |  | OU      | $2095628.10   | 0.37%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Providence Strategic Growth L.P.                      | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $180802.85    | 0.03%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Hidden Harbor Capital Partners Continuation Fund L.P. | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $14002899.35  | 2.47%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Warburg Pincus Capital Solutions Founders Fund, LP    | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $952744.04    | 0.17%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | KKR Rainbow Co-lnvest (Asset) L.P.                    | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | KY        |  | OU      | $5887670.75   | 1.04%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | One Equity Partners IX-B SCSp.                        | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $2859693.57   | 0.50%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Madison Dearborn Capital Partners IX                  | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $131148.00    | 0.02%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | PSG Europe II L.P.                                    | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | LU        |  | OU      | $1164502.31   | 0.21%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Sagard NewGen Pharma FPCI                             | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | FR        |  | OU      | $747289.05    | 0.13%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Peak Rock Capital Fund IV-C NUS                       | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $304049.71    | 0.05%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | GA Continuity Fund II, L.P.                           | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $6240384.25   | 1.10%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Providence Strategic Growth IV L.P.                   | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $2790298.32   | 0.49%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Portage Capital Solutions Intenational Fund I LP      | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | CA        |  | OU      | $1985542.68   | 0.35%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | The Resolute III Continuation Fund, L.P.              | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $34426256.08  | 6.08%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | PSG LM Sequel L.P.                                    | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $190982.00    | 0.03%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | ECI 12 Special Purpose LP                             | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | GB        |  | OU      | $15422300.79  | 2.72%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | LEP Red Rock Fund, L.P.                               | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $11990991.92  | 2.12%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Hg Saturn 4 B L.P.                                    | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | GB        |  | OU      | $15522.90     | 0.00%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Sagard NewGen FPCI                                    | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | FR        |  | OU      | $2527955.29   | 0.45%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Providence Strategic Growth III L.P.                  | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $1840292.58   | 0.32%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | PrimeStone Capital Fund ICAV                          | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | JE        |  | OU      | $688427.35    | 0.12%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Sagard Testing FPCI                                   | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | FR        |  | OU      | $4497517.46   | 0.79%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Sagard 4A FPCI and Sagard 4B FIPS (A Shares)          | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | FR        |  | OU      | $11427745.79  | 2.02%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | PSG Fidelity Co-Invest L.P.                           | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $1139449.16   | 0.20%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | PSG LM Sequel L.P.                                    | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $101078.00    | 0.02%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Sagard II-A FPCI and Sagard II-B FPCI                 | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | FR        |  | OU      | $309357.64    | 0.05%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Backed 2 LP                                           | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | JE        |  | OU      | $2013594.55   | 0.36%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | PSG V L.P.                                            | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $2778560.72   | 0.49%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Apheon AlliA                                          | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | BE        |  | OU      | $0.00         | 0.00%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Alto Capital V                                        | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | IT        |  | OU      | $2375005.83   | 0.42%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | C2 Capital Global Export-To-China Fund, L.P.          | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | KY        |  | OU      | $10456640.76  | 1.85%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Bain Capital Beacon Holdings, L.P.                    | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $29427068.10  | 5.20%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Apheon MidCap Buyout IV, SCSp                         | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | BE        |  | OU      | $18918978.62  | 3.34%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Epiris Fund III (B) L.P.                              | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | JE        |  | OU      | $3796391.16   | 0.67%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Stone Point CV, L.P.                                  | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $24182180.58  | 4.27%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | CF24XB SCSp                                           | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $12263708.84  | 2.17%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | PSG VI L.P.                                           | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $275462.66    | 0.05%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | KKR Sigma Co-lnvest II L.P.                           | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | KY        |  | OU      | $13070559.58  | 2.31%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Bregal Unternehmerkapital IV-B SCSp                   | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | LU        |  | OU      | $1375391.88   | 0.24%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Providence Strategic Growth II L.P.                   | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | US        |  | OU      | $894961.03    | 0.16%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | E.C.B. (Bastille) SCA                                 | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | BE        |  | OU      | $1173361.04   | 0.21%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | KKR Azur Co-lnvest L.P.                               | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | KY        |  | OU      | $4934428.90   | 0.87%             |  |  |  | Yes           | N/A                | On Loan: No      |
| N/A    | Elysium Acquisition LP                                | CUSIP: N/A<br>LEI: N/A       | Long             | EC               | PF                | GB        |  | OU      | $9906950.67   | 1.75%             |  |  |  | Yes           | N/A                | On Loan: No      |

### Signature

**Date Signed:** 2026-01-30

**Name of Applicant:** Carlyle AlpInvest Private Markets Secondaries Fund

**Signature:** Parker Hooper

**Name of Signer:** Parker Hooper

**Title:** Treasurer and Principal Financial Officer